COVID-19, Liver Cirrhosis
Conditions
Keywords
COVID-19, Liver cirrhosis, Clinical outcome
Brief summary
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Detailed description
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Interventions
None listed
Sponsors
Renmin Hospital of Wuhan University
LanZhou University
Minda Hospital Affiliated to Hubei University for Nationalities
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Tianjin Second People's Hospital
The Sixth People's Hospital of Shenyang
Guangxi Zhuang Autonomous Region
Shenzhen Third People's Hospital
Ankang Central Hospital
Xingtai People's Hospital
Dalian Sixth People's Hospital
The Central Hospital of Lishui City
The Affiliated Third Hospital of Jiangsu University
Suizhou Hospital, Hubei University of Medicine
Hepatopancreatobiliary Surgery Institute of Gansu Province
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\) Aged 18 or above; * 2\) Laboratory-confirmed COVID-19 infection; * 3\) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.
Exclusion criteria
* 1\) Pregnancy or unknown pregnancy status.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality of COVID-19 patients with liver cirrhosis | From illness onset of COVID-19 to death from any cause, up to 365 days | 7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Liver-related mortality of COVID-19 patients with liver cirrhosis | From illness onset of COVID-19 to death from liver-related cause, up to 365 days | 7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis |
| Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis | From hospital admission to death, up to 365 days | Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis |
| Baseline characteristics of COVID-19 patients with liver cirrhosis | 1 Day | Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis |
Countries
China
Outcome results
None listed